Data compiled by Redley Lamar · ChainSifter Intelligence
6Suppliers
4Customers
1Debt Items
20Related Chains
Source-Backed Evidence Depth
Apogee Therapeutics, Inc. (APGE) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
12Total relationships
3Distinct source URLs
9High confidence
0.840Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Apogee Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
GUGGENHEIM-SECURITIES-LLC
GUGGENHEIM-SECURITIES-LLC
90%
On March 24, 2026, Apogee Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, Stifel, Nicolaus & Company,…
JEFFERIES-LLC
JEFFERIES-LLC
90%
On March 24, 2026, Apogee Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, Stifel, Nicolaus & Company,…
SAMSUNG-BIOLOGICS
SAMSUNG-BIOLOGICS
90%
For the three months ended March 31, 2026 and 2025, the Company recognized $ 0.4 million and $ 1.7 million, respectively, of research and development expense in connection with the Samsung Biologics MSA.
STIFEL-NICOLAUS-COMPANY-INCORPORATED
STIFEL-NICOLAUS-COMPANY-INCORPORATED
90%
On March 24, 2026, Apogee Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, Stifel, Nicolaus & Company,…
TD-SECURITIES-USA-LLC
TD-SECURITIES-USA-LLC
90%
On March 24, 2026, Apogee Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, Stifel, Nicolaus & Company,…
SAMSUNG
SAMSUNG
80%
the PSA provides for Samsung to receive compensation, including for contractually obligated expenses, and an exit fee in the high single-digit millions.
Apogee Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
ANNAPURNA-AGGREGATOR-L-P
ANNAPURNA-AGGREGATOR-L-P
92%
Pursuant to the Revenue Share Agreement, in exchange for an upfront payment of $100.0 million (the "Tranche 1 Funding"), BXLS purchased from the Company the right to receive tiered revenue share paym…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from APGE graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from APGE graph: Reciprocal relationship from SNYN…
SNYNF
Sanofi
72%
e technologies, products or programs. Even if these patents are granted, they may be difficult to enforce. Further, any issued patents that we may license or own covering our programs could be narrow…
SAMSUNG-BIOLOGICS-CO-LTD
SAMSUNG-BIOLOGICS-CO-LTD
62%
g difficulties due to resource constraints, supply chain issues, human capital constraints, natural disasters or as a result of labor disputes or unstable political environments, including tariffs an…
Apogee Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
APGE-DEBT
Debt stack $8.0M
90%
Market cache reports total debt of $8.0M.
Apogee Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Apogee Therapeutics, Inc..
Apogee Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
APGE-OWNER-T-ROWE-PRICE-INVESTMENT-MANAGEME
T. Rowe Price Investment Management, Inc.
90%
13F overlay lists T. Rowe Price Investment Management, Inc. as top holder; 231 tracked holders.
Apogee Therapeutics, Inc. Extended Supply Chain Network
